A case of bullous dermatitis induced by erlotinib.
Herein, we report a case of bullous dermatitis that occurred in a 61-year-old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level. Skin reactions are the most common adverse drug reactions (ADRs) associated with epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, and acneiform rash is the most frequently reported ADR in patients treated with erlotinib. To our knowledge, this is the first case of bullous dermatitis induced by erlotinib. This report highlights the need for additional research in the field of skin toxicity of EGFR-TK inhibitors.
Oteri
Alessandro
A
Unit of Clinical Pharmacology, Department of Preclinical-Sciences LITA-Vialba, L. Sacco University Hospital, Università di Milano, Milan, Italy.
Cattaneo
Maria Teresa
MT
Filipazzi
Virginio
V
Ferrario
Sabrina
S
Gambaro
Anna
A
Isabella
Luigi
L
Tosca
Nicoletta
N
Clementi
Emilio
E
Radice
Sonia
S
Piazza
Elena
E
D000230:Adenocarcinoma / Q000188:drug therapy; D003872:Dermatitis / Q000209:etiology* / Q000473:pathology; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000188:drug therapy
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors